Bulletin
Investor Alert

Frequency Therapeutics Inc.

NAS: FREQ

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Apr 19, 2021, 7:55 p.m.

/zigman2/quotes/214411420/composite

$

9.26

Change

-0.16 -1.70%

Volume

Volume 8,688

Quotes are delayed by 20 min

/zigman2/quotes/214411420/composite

Today's close

$ 9.59

$ 9.42

Change

-0.17 -1.77%

Day low

Day high

$9.16

$9.96

Open

52 week low

52 week high

$7.34

$58.37

Open

Insider Actions for Frequency Therapeutics Inc.

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
03/01/2021 David L. Lucchino
President and CEO; Director
192   Disposition at $52.11 per share. 10,005
03/01/2021 David L. Lucchino
President and CEO; Director
4,202   Disposition at $51.76 per share. 217,495
03/01/2021 David L. Lucchino
President and CEO; Director
2,688   Disposition at $50 per share. 134,400
03/01/2021 David L. Lucchino
President and CEO; Director
1,255   Disposition at $48.85 per share. 61,306
03/01/2021 David L. Lucchino
President and CEO; Director
1,079   Disposition at $47.84 per share. 51,619
03/01/2021 David L. Lucchino
President and CEO; Director
9,416   Derivative/Non-derivative trans. at $0.61 per share. 5,743
02/08/2021 David L. Lucchino
President and CEO; Director
5,518   Disposition at $57.5 per share. 317,285
02/08/2021 David L. Lucchino
President and CEO; Director
5,518   Disposition at $55 per share. 303,490
02/08/2021 David L. Lucchino
President and CEO; Director
5,518   Disposition at $52.5 per share. 289,695
02/08/2021 David L. Lucchino
President and CEO; Director
16,554   Derivative/Non-derivative trans. at $0.61 per share. 10,097
02/03/2021 David L. Lucchino
President and CEO; Director
5,518   Disposition at $50 per share. 275,900
02/03/2021 David L. Lucchino
President and CEO; Director
5,518   Disposition at $47.5 per share. 262,105
02/03/2021 Christopher R. Loose
Chief Scientific Officer
2,000   Disposition at $47.19 per share. 94,380
02/03/2021 David L. Lucchino
President and CEO; Director
11,036   Derivative/Non-derivative trans. at $0.61 per share. 6,731
02/02/2021 David L. Lucchino
President and CEO; Director
9   Disposition at $47.36 per share. 426
02/02/2021 David L. Lucchino
President and CEO; Director
1,709   Disposition at $46.84 per share. 80,049
02/02/2021 David L. Lucchino
President and CEO; Director
3,800   Disposition at $45.76 per share. 173,888
02/02/2021 Christopher R. Loose
Chief Scientific Officer
8,000   Disposition at $45.02 per share. 360,160
02/02/2021 David L. Lucchino
President and CEO; Director
5,518   Derivative/Non-derivative trans. at $0.61 per share. 3,365
02/01/2021 David L. Lucchino
President and CEO; Director
2,702   Disposition at $44.58 per share. 120,455
02/01/2021 David L. Lucchino
President and CEO; Director
8,900   Disposition at $43.71 per share. 389,019
02/01/2021 David L. Lucchino
President and CEO; Director
18,600   Disposition at $42.85 per share. 797,010
02/01/2021 David L. Lucchino
President and CEO; Director
2,900   Disposition at $41.29 per share. 119,741
02/01/2021 David L. Lucchino
President and CEO; Director
33,102   Derivative/Non-derivative trans. at $0.61 per share. 20,192
01/27/2021 David L. Lucchino
President and CEO; Director
9,196   Disposition at $42.5 per share. 390,830
01/27/2021 Christopher R. Loose
Chief Scientific Officer
8,000   Disposition at $42.5 per share. 340,000
01/27/2021 David L. Lucchino
President and CEO; Director
9,196   Derivative/Non-derivative trans. at $0.61 per share. 5,609
01/06/2021 David L. Lucchino
President and CEO; Director
9,496   Disposition at $40 per share. 379,840
01/06/2021 David L. Lucchino
President and CEO; Director
2,319   Disposition at $39.37 per share. 91,299
01/06/2021 David L. Lucchino
President and CEO; Director
4,164   Disposition at $38.26 per share. 159,314
01/06/2021 David L. Lucchino
President and CEO; Director
10,707   Disposition at $37.45 per share. 400,977
01/06/2021 David L. Lucchino
President and CEO; Director
900   Disposition at $36.13 per share. 32,517
01/06/2021 David L. Lucchino
President and CEO; Director
27,586   Derivative/Non-derivative trans. at $0.61 per share. 16,827
01/04/2021 David L. Lucchino
President and CEO; Director
100   Disposition at $35.46 per share. 3,546
01/04/2021 David L. Lucchino
President and CEO; Director
11,763   Disposition at $33.81 per share. 397,707
01/04/2021 David L. Lucchino
President and CEO; Director
22,241   Disposition at $32.89 per share. 731,506
01/04/2021 David L. Lucchino
President and CEO; Director
14,477   Derivative/Non-derivative trans. at $0.61 per share. 8,830
01/04/2021 David L. Lucchino
President and CEO; Director
3,913   Derivative/Non-derivative trans. at $0.61 per share. 2,386
12/24/2020 Timothy Joseph Barberich
Director
102,089   Gift at $0 per share. 0
12/17/2020 David L. Lucchino
President and CEO; Director
1,120   Disposition at $42.64 per share. 47,756
12/17/2020 Christopher R. Loose
Chief Scientific Officer
2,000   Disposition at $42.5 per share. 85,000
12/17/2020 Christopher R. Loose
Chief Scientific Officer
6,000   Disposition at $40 per share. 240,000
12/17/2020 David L. Lucchino
President and CEO; Director
1,120   Derivative/Non-derivative trans. at $0.61 per share. 683

Transaction Summary

Total insider purchases and sales reported to the SEC

Timeframe Transactions Shares
Last 3 months
6 Purchases
21 Sales
84,822
102,822
Last 6 months
17 Purchases
52 Sales
199,488
471,631
Last 12 months
21 Purchases
91 Sales
314,079
686,295

Officers and Executives

Mr. David L. Lucchino
President, Chief Executive Officer & Director
Mr. Richard Mitrano
Vice President-Finance & Operations
Mr. Peter P. Pfreundschuh
Chief Financial Officer
Dr. Dana Charles Hilt
Chief Medical Officer
Dr. Jeffrey Hrkach
Senior Vice President-Technology Development
Dr. Christopher R. Loose
Chief Scientific Officer
Dr. Carl P. LeBel
Chief Development Officer
Mr. Ajay Rai
Vice President-Business Development
Mr. Jason Glashow
Senior Vice President-Corporate Affairs
Dr. Quentin McCubbin
Chief Manufacturing Officer
Dr. Will J. McLean
Vice President-Biology & Regenerative Medicine
Dr. William W. Chin
Executive VP-Clinical & Translational Science
Dr. Kevin Frank
SVP-Strategic Marketing & New Product Planning
Ms. Wendy S. Arnold
Chief People Officer
Mr. Michael D. Bookman
Secretary & General Counsel
Ms. Susan B. Stewart
Chief Regulatory Officer
Mr. Marc A. Cohen
Chairman
Ms. Cynthia L. Feldmann
Independent Director
Mr. Timothy Joseph Barberich
Independent Director
Dr. Robert S. Langer
Independent Director
Mr. Joel S. Marcus
Independent Director
Mr. Michael L. Huang
Independent Director
Link to MarketWatch's Slice.